EXEL · Exelixis, Inc. · Executive Compensation

$69.00 -0.84 (-1.20%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$16.84B

244.01M

Volume · Nov 13 1.52M Avg daily vol (3M) 2.41M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,306,040	—	$30,539,552	—	$1,382,591	$11,000	$33,239,183
Amy Peterson	Former Executive Vice President, Medical Affairs, and Chief Medical Officer	$614,496	—	$8,442,574	—	—	$2,088,964	$11,146,034
Christopher Senner	Executive Vice President and Chief Financial Officer	$822,823	—	$9,343,867	—	$470,782	$11,000	$10,648,472
Dana T. Aftab	Executive Vice President, Research and Development	$659,058	—	$9,479,940	—	$397,250	$11,000	$10,547,248
Jeffrey J. Hessekiel	Former Executive Vice President, General Counsel	$672,374	—	$8,309,218	—	—	$11,000	$8,992,592
Brenda J. Hefti	J.D., Ph.D. Senior Vice President and General Counsel	$454,545	—	$3,451,975	—	$286,751	$11,000	$4,204,271

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,252,636	—	$10,012,388	—	$1,456,024	$11,000	$12,732,048
Christopher Senner	Executive Vice President and Chief Financial Officer	$788,288	—	$3,402,273	—	$478,599	$11,000	$4,680,160
Amy Peterson	Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer	$654,337	—	$3,402,273	—	$378,405	$11,000	$4,446,015
Jeffrey J. Hessekiel	Executive Vice President, General Counsel	$685,882	—	$2,624,591	—	$415,243	$11,000	$3,736,716
Dana T. Aftab	Executive Vice President, Discovery and Translational Research and Chief Scientific Officer	$619,316	—	$2,624,591	—	$361,671	$11,000	$3,616,578

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,192,001	—	$14,259,313	—	$960,993	$11,000	$16,423,307
Amy Peterson	Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer	$201,846	$265,530	$5,220,000	$1,590,000	$90,470	$11,000	$7,378,846
Dana T. Aftab	Executive Vice President, Discovery and Translational Research and Chief Scientific Officer	$577,920	—	$4,770,110	—	$294,112	$11,000	$5,653,142
Christopher Senner	Executive Vice President and Chief Financial Officer	$746,726	—	$3,888,899	—	$301,006	$11,000	$4,947,631
Jeffrey J. Hessekiel	Executive Vice President, General Counsel	$657,175	—	$3,629,606	—	$264,908	$11,000	$4,562,689

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,144,250	—	$14,567,256	—	$1,155,039	$11,000	$16,877,545
Vicki Goodman	Former Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer	$622,500	$500,000	$4,687,500	—	$325,000	$11,000	$6,146,000
Christopher Senner	Executive Vice President and Chief Financial Officer	$716,172	—	$4,093,312	—	$361,786	$11,000	$5,182,270
Jeffrey J. Hessekiel	Executive Vice President, General Counsel	$630,285	—	$3,656,426	—	$318,399	$11,000	$4,616,110

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gisela Schwab	Former President, Product Development and Medical Affairs and Chief Medical Officer	$557,210	—	$7,020,502	$1,280,412	—	$11,000	$8,869,124
Michael M. Morrissey	President and Chief Executive Officer	$1,093,875	—	—	$5,160,513	$1,265,043	$11,000	$7,530,431
Christopher Senner	Executive Vice President and Chief Financial Officer	$679,568	—	$1,367,037	—	$399,507	$11,000	$2,457,112
Jeffrey J. Hessekiel	Executive Vice President, General Counsel and Secretary	$599,135	—	$1,217,547	—	$347,069	$11,000	$2,174,751
Patrick J. Haley	Executive Vice President, Commercial	$526,477	—	$1,269,437	—	$308,958	$11,000	$2,115,872
Peter Lamb	Ph. D. Executive Vice President, Scientific Strategy and Chief Scientific Officer	$560,850	—	$1,052,607	—	$337,605	$11,000	$1,962,062

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,058,216	$128,159	—	—	$1,153,437	$10,000	$2,349,812
Patrick J. Haley	Executive Vice President, Commercial	$500,953	$21,420	$763,000	—	$269,280	$10,000	$1,564,653
Gisela Schwab	Former President, Product Development and Medical Affairs and Chief Medical Officer	$744,044	$37,813	—	—	$610,409	$10,000	$1,402,266
Christopher Senner	Executive Vice President and Chief Financial Officer	$648,358	$27,434	—	—	$379,176	$10,000	$1,064,968
Jeffrey J. Hessekiel	Executive Vice President, General Counsel and Secretary	$576,091	$24,376	—	—	$306,443	$10,000	$916,910

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$1,005,201	—	—	—	$1,118,854	$8,500	$2,132,555
Gisela Schwab	Former President, Product Development and Medical Affairs and Chief Medical Officer	$710,751	—	—	—	$409,231	$8,500	$1,128,482
Christopher Senner	Executive Vice President and Chief Financial Officer	$622,866	—	—	—	$310,893	$8,500	$942,259
Jeffrey J. Hessekiel	Executive Vice President, General Counsel and Secretary	$553,934	—	—	—	$276,240	$8,500	$838,674
Peter Lamb	Executive Vice President, Scientific Strategy and Chief ScientificOfficer	$517,617	—	—	—	$258,589	$8,500	$784,706

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief Executive Officer	$945,080	—	—	$3,111,403	$1,000,000	$8,500	$5,064,983
Gisela Schwab	President, Product Development and Medical Affairs and Chief Medical Officer	$672,301	—	—	$1,227,500	$466,156	$8,500	$2,374,457
Christopher Senner	Executive Vice President and Chief Financial Officer	$594,740	—	—	$1,227,500	$338,074	$8,500	$2,168,814
Jeffrey J. Hessekiel	Executive Vice President and General Counsel	$531,880	—	—	$1,227,500	$301,836	$8,500	$2,069,716
Peter Lamb	Executive Vice President, Scientific Strategy and Chief ScientificOfficer	$493,570	—	—	$1,180,295	$311,202	$8,500	$1,993,567

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael M. Morrissey	President and Chief ExecutiveOfficer	$891,781	$675,750	$1,952,800	$5,911,152	—	$8,100	$9,439,583
Gisela Schwab	President, Product Development and Medical Affairs and Chief MedicalOfficer	$629,493	$318,000	$1,830,750	$1,847,235	—	$8,100	$4,633,578
Christopher Senner	Executive Vice President and Chief FinancialOfficer	$562,120	$255,150	$1,525,625	$1,539,363	—	$8,100	$3,890,358
Peter Lamb	Executive Vice President, Scientific Strategy and Chief ScientificOfficer	$473,190	$214,245	$1,342,550	$1,354,639	—	$8,100	$3,392,724
Jeffrey J. Hessekiel	Executive Vice President and GeneralCounsel	$507,067	$229,970	$1,220,500	$1,231,490	—	$7,076	$3,196,103

Executive changes

Person	Role	Change	Effective	Filed
Jack L. Wyszomierski	Director	Already on the board Since at least 2004: re-election or new board role	2026-05-26	2026-05-29
Julie Anne Smith	Director	Already on the board Since at least 2016: re-election or new board role	2026-05-26	2026-05-29
George Poste, DVM, Ph.D., FRS	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
Robert L. Oliver, Jr.	Director	Appointed	2026-05-26	2026-05-29
Stelios Papadopoulos, Ph.D.	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
David E. Johnson	Director	Already on the board Since at least 2023: re-election or new board role	2026-05-26	2026-05-29
Michael M. Morrissey, Ph.D.	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
Tomas J. Heyman	Director	Already on the board Since at least 2023: re-election or new board role	2026-05-26	2026-05-29
Maria C. Freire, Ph.D.	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
S. Gail Eckhardt, M.D.	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
Mary C. Beckerle, Ph.D.	Director	Already on the board Since at least 2024: re-election or new board role	2026-05-26	2026-05-29
Brenda Hefti, J.D., Ph.D.	General Counsel	Appointed	2025-11-07	2025-11-07
Jeffrey Hessekiel, J.D.	Executive Vice President and General Counsel	Resigned	2025-11-07	2025-11-07
Dana T. Aftab, Ph.D.	Executive Vice President, Research and Development	Appointed	2025-08-29	2025-08-29
S. Gail Eckhardt, M.D.	Board of Directors	Appointed	2024-01-05	2024-01-08
Mary C. Beckerle, Ph.D.	Board of Directors	Appointed	2024-01-05	2024-01-08
Lance Willsey	Board of Directors	Resigned	2023-05-07	2023-05-08
Peter Lamb	Executive Vice President, Scientific Strategy	Appointed	2022-12-15	2022-12-15

Leadership

Michael M. Morrissey CEO, Board Member
Michael Morrissey CEO, Board Member
Christopher Senner CFO
Brenda Hefti, J.D., Ph.D. General Counsel
Brenda J. Hefti General Counsel
Alan M. Garber, M.D., Ph.D. Board Member
Carl B. Feldbaum, Esq. Board Member
Charles Cohen, Ph.D. Board Member
David E. Johnson Board Member
George Poste Board Member
George Poste, DVM, Ph.D., FRS Board Member
Jack L. Wyszomierksi Board Member
Jack L. Wyszomierski Board Member
Jacky Wright Board Member
Julie Anne Smith Board Member
Lance Willsey, M.D. Board Member
Maria C. Freire Board Member
Maria C. Freire, Ph.D. Board Member
Mary C. Beckerle Board Member
Mary C. Beckerle, Ph.D. Board Member
Michael M. Morrissey, Ph.D. Board Member
Robert L. Oliver Board Member
Robert L. Oliver, Jr. Board Member
S. Gail Eckhardt Board Member
S. Gail Eckhardt, M.D. Board Member
Stelios Papadopoulos Board Member
Stelios Papadopoulos, Ph.D. Board Member
Tomas J. Heyman Board Member
Vincent T. Marchesi, M.D., Ph.D. Board Member

Key facts CIK 939767 CUSIP 30161Q104 13F (30d) 616 filings 567 filers Visit website Investor relations